Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial

NCT01965223 is registered in ClinicalTrials.gov with Trans Tasman Radiation Oncology Group as lead sponsor.

NCT NCT01965223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01965223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial
Lead sponsor
Trans Tasman Radiation Oncology Group
Phase
Not applicable
Overall status
Completed
Start date
February 4, 2015
Completion date
July 27, 2020
Enrollment
90 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastases to the lung